Inducible chimeric cytokine receptors
AssigneeAllogene Therapeutics, Inc.
InventorsAndrew Ross NAGER, Spencer PARK, Javier Fernando CHAPARRO RIGGERS, Regina Junhui LIN, Thomas John VAN BLARCOM
Life of this patent
Estimating the term…
Abstract
The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.
Claims76
An inducible chimeric cytokine receptor comprising:
- a dimerization domain;
- a tyrosine kinase activating domain;
- and
- a tyrosine effector domain,
- wherein the tyrosine effector domain comprises at least two STAT-activation domains of, or derived from, two receptors;
- or wherein the tyrosine effector domain comprises at least one STAT-activation domain of, or derived from, a receptor and a portion of the cytoplasmic tail of, or derived from, at least one receptor tyrosine kinase (RTK).
5-7. (canceled)
17-18. (canceled)
(canceled)
(canceled)
(canceled)
63-70. (canceled)
(canceled)
80-87. (canceled)
90-106. (canceled)
109-110. (canceled)
Dependencies are inferred from the claim text.